1-7 of 7
Kai Riecke
Close
Sort by
Journal Articles

Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma

Heinz Ludwig, Univ. Prof. Dr., Katja Weisel, MD, Maria Teresa Petrucci, MD, Xavier Leleu, MD, Anna Maria Cafro, MD, Garderet Laurent, MD, Niklas Zojer, MD, Robin Foa, MD, Richard Greil, MD, Ibrahim Yakoub-Agha, MD PhD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Monika Engelhardt, MD
Journal: Blood
Blood (2014) 124 (21): 2111.
https://doi.org/10.1182/blood.V124.21.2111.2111
Published: 2014
Journal Articles

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Michael Steurer, MD, Marco Montillo, MD, Lydia Scarfò, Francesca Romana Mauro, Johannes Andel, MD, Sophie Wildner, MD, Livio Trentin, MD, Ann Janssens, MD, Sonja Burgstaller, MD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Marco Gobbi, MD
Journal: Blood
Blood (2014) 124 (21): 1996.
https://doi.org/10.1182/blood.V124.21.1996.1996
Published: 2014
Journal Articles

Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans

Clinical Trials & Observations Brief Report
Lucas T. van Eijk, Aaron S. E. John, Frank Schwoebel, Luciana Summo, Stéphanie Vauléon, Stefan Zöllner, Coby M. Laarakkers, Matthijs Kox, Johannes G. van der Hoeven, Dorine W. Swinkels, Kai Riecke, Peter Pickkers
Journal: Blood
Blood (2014) 124 (17): 2643–2646.
https://doi.org/10.1182/blood-2014-03-559484
Published: 2014
Includes: Supplemental data
Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study

Heinz Ludwig, MD, Katja Weisel, MD, Monika Engelhardt, MD, Richard Greil, MD, Anna Maria Cafro, MD, Maria Teresa Petrucci, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD
Journal: Blood
Blood (2013) 122 (21): 1951.
https://doi.org/10.1182/blood.V122.21.1951.1951
Published: 2013
Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Marco Gobbi, MD, Michael Steurer, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Ann Janssens, MD, Livio Trentin, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD
Journal: Blood
Blood (2013) 122 (21): 1635.
https://doi.org/10.1182/blood.V122.21.1635.1635
Published: 2013
Journal Articles

Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.

Kai Riecke, MD, Stefan Zöllner, PhD, Malcolm Boyce, MD, Stephanie Vauléon, PhD, Dorine W. Swinkels, MD, PhD, Thomas Dümmler, PhD, Luciana Summo, PharmD PhD, Coby Laarakkers, BSc, Frank Schwoebel, PhD, Frank Fliegert, MD
Journal: Blood
Blood (2012) 120 (21): 2342.
https://doi.org/10.1182/blood.V120.21.2342.2342
Published: 2012
Journal Articles

Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer Nox-H94 On Serum Iron During Experimental Human Endotoxemia

Lucas van Eijk, MD, Dorine W. Swinkels, MD, PhD, John Aaron, Frank Schwoebel, PhD, Frank Fliegert, MD, Luciana Summo, PharmD PhD, Vauleon Stéphanie, PhD, Coby Laarakkers, BSc, Kai Riecke, MD, Peter Pikkers, MD PhD
Journal: Blood
Blood (2012) 120 (21): 3452.
https://doi.org/10.1182/blood.V120.21.3452.3452
Published: 2012